Despite threats of resistance, the utility of T-DXd has been exemplified through its FDA-approved use in non-gynecologic malignancies, including metastatic breast cancer, HER2-positive gastric cancer, and HER2-mutated non-small-cell lung cancer [39,40,41]. This evidence concerns the gene ERBB2 and gastric cancer.